SDC2 and neoplasm: These in vivo studies demonstrate that stromal‐derived SDC2 regulates primary tumour growth and metastasis and modulates TGFβ signalling within the TME, suggesting that blocking stromal‐derived syndecan‐2 has the potential to inhibit tumour growth and metastasis.